Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BOrient Pharma Co., Ltd. 〉Multiple-Phasic Release Technology (MPRT)

Multiple-Phasic Release Technology (MPRT)

Multiple-Phasic Release Technology (MPRT)

Orient Pharma's MPRT can reduce the risk of local irritation and toxicity, offer predictable bioavailability, reduce dose dumping, minimize fluctuations in plasma concentration, while overcomes the challenges for manufacturing pellets in tablets.

Request for Collaboration
Overview
Through Orient Pharma's patented technology, incompatible ingredients or drugs with different release profiles can be enclosed in a single capsule or tablet for the development of new drugs.
Application
Orient Pharma and Durect (US; NASDAQ: DRRX) are jointly developing ORADUR-MPH for treatment of attention deficit hyperactivity disorder(ADHD) . By combining Orient's MPRT technology with Durect's patented Excipient, the designed drug profile will not only enhance drug efficacy, but also be tamper-resistant , thus sets it apart from the current competitors.

 
Collaboration Options
Open for global collaboration
People who like this also like
  • Isoniazid without liver toxicityIsoniazid without liver toxicity
  • PHN013 (Orphan drug;ITP)PHN013 (Orphan drug;ITP)
  • Lead discoveryLead discovery
  • PHN014 (Acute ischemia stroke)PHN014 (Acute ischemia stroke)
  • Digital Surgical Guide & Artificial Teeth ServiceDigital Surgical Guide & Artificial Teeth Service
  • TAT-HOXB4TAT-HOXB4
  • PHDC-01PHDC-01
  • Medical Image Processing Apparatus and Breast Image Processing Method ThereofMedical Image Processing Apparatus and Breast Image Processing Method Thereof
  • TRIA11TRIA11
  • Homogeneous antibody drugs (CHO-H01, H02, H03)Homogeneous antibody drugs (CHO-H01, H02, H03)